Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases-Reference-Cited by-同舟云学术

Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases

Published:2020-06-17 Issue:7 Volume:19 Page:861-872
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Cantini Fabrizio¹^ORCID,Blandizzi Corrado²^ORCID,Niccoli Laura¹^ORCID,Petrone Linda³^ORCID,Goletti Delia³^ORCID

Affiliation:

1. Rheumatology Department, Hospital of Prato, Prato, Italy

2. Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

3. Translational Research Unit, Department of Epidemiology and Preclinical Research, “L. Spallanzani” National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1774550

Reference101 articles.

1. European medicine Agency (EMA). Xeljanz (International non-proprietary name: tofacitinib) assessment report. EMEA/H/C/004214/0000. Committee for Medical Products for Human Use (CHMP), EMA/853224/2016; 2017January 26. [cited 2019 Dec 22]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/xeljanz-epar-public-assessment-report_en.pdf

2. European medicine Agency (EMA). Olumiant (International non-proprietary name: baricitinib) assessment report. EMEA/H/C/004085/0000. Committee for Medical Products for Human Use (CHMP), EMA/13493/2017; 2016 December 15. [cited 2019 Dec 22]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant

3. European medicine Agency (EMA). Rinvoq (International non-proprietary name: upadacitinib) assessment report. EMEA/H/C/004760/0000. Committee for Medical Products for Human Use (CHMP), EMA/608624/2019; 2019 Oct 17. [cited 2019 Dec 22]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq

4. US Food and Drug Administration. FDA approves xeljanz for rheumatoid arthritis. 2012 Nov 6. [cited 2019 Dec 22]. Available from: https://www.drugs.com/newdrugs/fda-approves-xeljanz-rheumatoid-arthritis-3558.html

5. US Food and Drug Administration. FDA approves olumiant for rheumatoid arthritis. 2018 Jun 1. [cited 2019 Dec 22]. Available from: https://www.drugs.com/newdrugs/fda-approves-olumiant-baricitinib-2-mg-adults-moderately-severely-active-rheumatoid-arthritis-4760.html

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus;Journal of the European Academy of Dermatology and Venereology;2024-08-16

2. (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review;Clinical Microbiology and Infection;2024-08

3. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16

4. Actualización de las Guías para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología 2023;Reumatología Clínica;2024-05

5. Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023;Reumatología Clínica (English Edition);2024-05